Epi proLung®

Lung cancer is the leading cause of cancer death for men and women. Starting from the existing product Epi proLung®, we are developing a blood-based test that detects the presence of lung cancer in blood plasma. This improved version will detect both the SHOX2 biomarker and the proprietary PTGER4 DNA methylation biomarker. We believe such a blood test has a broad variety of possible future clinical applications in the detection of lung cancer. Epi proLung® has the potential to be used as a confirmatory test for positively tested patients in a low dose spiral computed tomography (LDCT) screening and alternatively as an early detection test to guide patients into additional imaging-based diagnostic procedures, such as LDCT or others.

The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 672680.